Robotic Chemistry Yields Promising New Antibiotic Candidate in Fight Against Drug Resistance
Table of Contents
A groundbreaking study demonstrates a novel approach to antibiotic discovery, leveraging robotics and advanced chemical techniques to rapidly identify a potential new drug candidate to combat the growing threat of antibiotic-resistant infections.
The world is facing a mounting crisis as bacteria increasingly resist existing treatments, leading to over one million preventable deaths annually. Routine medical procedures – from hip replacements to chemotherapy – are becoming increasingly risky due to the potential for untreatable infections. Now, researchers at the University of York have unveiled a potentially game-changing methodology for accelerating the discovery of new antibiotics, detailed in a recent publication in Nature Communications.
A New Approach to an Old Problem
Traditionally, drug discovery is a lengthy and expensive process. However, a team led by Dr. Angelo Frei at the University of York’s Department of Chemistry has pioneered a new strategy focused on metal-based compounds. Unlike most modern antibiotics, which are carbon-based and “flat,” metal complexes possess a three-dimensional structure. This unique geometry allows them to interact with bacteria in novel ways, potentially circumventing the resistance mechanisms that have rendered many existing drugs ineffective.
“We have to think differently,” stated a senior researcher involved in the project. “The pipeline for new antibiotics has been running dry for decades, and traditional screening methods are simply too slow.”
‘Click’ Chemistry and Automation Supercharge Discovery
The Frei Lab utilized robotics and a technique known as “click chemistry” – a highly efficient method for joining molecular components – to dramatically accelerate the drug discovery process. Postdoctoral researcher Dr. David Husbands employed an automated platform to combine nearly 200 different “ligands” (molecules that surround a metal center) with five different metals.
The result? The synthesis of over 700 new metal complexes in under a week – a feat that would typically require months of manual labor. Following synthesis, the team rigorously screened these compounds for both antibacterial activity and toxicity to healthy human cells, identifying six promising lead candidates.
Iridium Compound Shows Exceptional Promise
One compound, based on the metal iridium, particularly stood out. It demonstrated high effectiveness against bacteria, including strains similar to the deadly MRSA (Methicillin-resistant Staphylococcus aureus), while exhibiting low toxicity to human cells. This favorable profile suggests a high “therapeutic index,” making it a strong contender for further drug development.
“The iridium compound we discovered is exciting, but the real breakthrough is the speed at which we found it,” explained Dr. Frei. “By combining smart ‘click’ chemistry with automation, we have demonstrated that we can explore vast, untapped areas of chemical space at unprecedented speed. We aren’t just looking for one drug; we are proving a methodology that can help us find the ‘needle in the haystack’ much faster.”
Challenging Misconceptions About Metal-Based Drugs
Historically, there has been a perception that metal-based drugs are inherently toxic. However, data from the Community for Open Antimicrobial Drug Discovery (CO-ADD) suggests otherwise. According to this data, metal complexes actually have a higher “hit rate” for exhibiting antibacterial properties without being toxic compared to standard organic molecules.
The University of York team is now focused on understanding precisely how their new iridium compound attacks bacteria and is expanding their robotic platform to test a wider range of metals. They hope their methodology will encourage broader exploration of metal complexes within the scientific community and pharmaceutical industry.
This rapid-synthesis method also holds potential beyond antibiotic discovery, with applications in fields such as the development of new catalysts for industrial processes. The team’s work represents a significant step forward in the fight against drug-resistant infections and offers a beacon of hope in a critical global health challenge.
Source: Journal reference: DOI: 10.1038/s41467-025-67341-z
